TRIM7

Summary

TRIM7 (tripartite motif containing 7, HGNC:16278) is a protein-coding gene on chromosome 5q35.3, encoding E3 ubiquitin-protein ligase TRIM7 (Q9C029). E3 ubiquitin-protein ligase that have both tumor-promoting and tumor-suppressing activities and functions in several biological processes including innate immunity, regulation of ferroptosis as well as cell proliferation and migration.

The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1, a B-box type 2, and a coiled-coil region. The protein localizes to both the nucleus and the cytoplasm, and may represent a participant in the initiation of glycogen synthesis. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 81786 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 82 total
• MANE Select transcript: NM_203293

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16278
Approved symbol	TRIM7
Name	tripartite motif containing 7
Location	5q35.3
Locus type	gene with protein product
Status	Approved
Aliases	RNF90, GNIP
Ensembl gene	ENSG00000146054
Ensembl biotype	protein_coding
OMIM	609315
Entrez	81786

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000274773, ENST00000334421, ENST00000393315, ENST00000393319, ENST00000422067, ENST00000504241, ENST00000509199, ENST00000946601

RefSeq mRNA: 6 — MANE Select: NM_203293 NM_033342, NM_203293, NM_203294, NM_203295, NM_203296, NM_203297

CCDS: CCDS43414, CCDS4462, CCDS4463, CCDS4464

Canonical transcript exons

ENST00000274773 — 7 exons

Exon	Start	End
ENSE00001149534	181198183	181198218
ENSE00001149544	181198690	181198805
ENSE00001149553	181199095	181199117
ENSE00001402990	181204589	181205196
ENSE00001867676	181193924	181195677
ENSE00003510089	181203545	181203640
ENSE00003565994	181199851	181200081

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 96.60.

FANTOM5 (CAGE): breadth broad, TPM avg 2.7419 / max 51.6302, expressed in 861 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
65354	2.5083	825
65353	0.1866	105
65355	0.0469	16

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vastus lateralis	UBERON:0001379	96.60	gold quality
quadriceps femoris	UBERON:0001377	96.19	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.03	gold quality
lower esophagus mucosa	UBERON:0035834	94.87	gold quality
biceps brachii	UBERON:0001507	94.77	gold quality
gastrocnemius	UBERON:0001388	94.67	gold quality
muscle of leg	UBERON:0001383	94.64	gold quality
skeletal muscle tissue	UBERON:0001134	94.57	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.09	gold quality
cerebellar hemisphere	UBERON:0002245	93.81	gold quality
cerebellar cortex	UBERON:0002129	93.62	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.36	gold quality
tibialis anterior	UBERON:0001385	93.12	gold quality
deltoid	UBERON:0001476	92.67	gold quality
skin of leg	UBERON:0001511	92.52	gold quality
cerebellum	UBERON:0002037	92.12	gold quality
esophagus mucosa	UBERON:0002469	91.88	gold quality
skin of abdomen	UBERON:0001416	91.73	gold quality
gingival epithelium	UBERON:0001949	91.07	gold quality
esophagus squamous epithelium	UBERON:0006920	91.01	gold quality
zone of skin	UBERON:0000014	90.85	gold quality
body of tongue	UBERON:0011876	90.53	gold quality
muscle tissue	UBERON:0002385	89.85	gold quality
upper arm skin	UBERON:0004263	89.62	gold quality
gingiva	UBERON:0001828	89.07	gold quality
apex of heart	UBERON:0002098	86.21	gold quality
pharyngeal mucosa	UBERON:0000355	86.15	gold quality
upper leg skin	UBERON:0004262	86.00	gold quality
oral cavity	UBERON:0000167	84.13	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting TRIM7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-3194-3P	98.83	66.22	1167
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-3135B	98.61	65.33	1470
HSA-MIR-6852-3P	98.54	67.60	1468
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-581	98.39	67.42	835
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-5691	98.23	67.02	1335
HSA-MIR-6805-3P	98.23	67.02	1334
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-892B	98.00	67.11	821

Literature-anchored findings (GeneRIF, showing 18)

• GNIP, a novel protein that binds and activates glycogenin, the self-glucosylating initiator of glycogen biosynthesis (PMID:11916970)
• TRIM28 is a specific SUMO E3 ligase of interferon regulatory factor (IRF)7 and negatively regulates its activity and interferon (IFN)-based antiviral responses, in support of the expanding roles of TRIM proteins which regulate innate immunity. (PMID:21940674)
• GNIP1 is an ubiquitin ligase with a markedly glycogenic effect in skeletal muscle. (PMID:29466708)
• TRIM7 expression was elevated in human hepatocellular carcinoma (HCC) tissues. TRIM7 knockdown inhibited HCC cell proliferation and induced a G1/S checkpoint. The DUSP6/p38 signaling mediated the functions of TRIM7 in human HCC cells. (PMID:30850165)
• TRIM7 promotes proliferation and migration of vascular smooth muscle cells in atherosclerosis through activating c-Jun/AP-1. (PMID:31625258)
• The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein. (PMID:31802035)
• E3 ubiquitin ligase TRIM7 negatively regulates NF-kappa B signaling pathway by degrading p65 in lung cancer. (PMID:31958511)
• N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. (PMID:32853985)
• Crystal structure and mutational analysis of the human TRIM7 B30.2 domain provide insights into the molecular basis of its binding to glycogenin-1. (PMID:33989636)
• TRIM7 inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity. (PMID:34062120)
• Negative Regulation of RNF90 on RNA Virus-Triggered Antiviral Immune Responses Targeting MAVS. (PMID:34512666)
• TRIM7 suppresses cell invasion and migration through inhibiting HIF-1alpha accumulation in clear cell renal cell carcinoma. (PMID:34936717)
• A C-terminal glutamine recognition mechanism revealed by E3 ligase TRIM7 structures. (PMID:35982226)
• GNIP1 functions both as a scaffold protein and an E3 ubiquitin ligase to regulate autophagy in lung cancer. (PMID:36042481)
• TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells. (PMID:36067704)
• Study on the expression of TRIM7 in peripheral blood mononuclear cells of patients with sepsis and its early diagnostic value. (PMID:36402943)
• TRIM7 inhibits encephalomyocarditis virus replication by activating interferon-beta signaling pathway. (PMID:37023504)
• The E3 ligase TRIM7 suppresses the tumorigenesis of gastric cancer by targeting SLC7A11. (PMID:38509147)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Trim7	ENSMUSG00000040350
rattus_norvegicus	Trim7	ENSRNOG00000002469

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890), TRIM63 (ENSG00000158022)

Protein

Protein identifiers

E3 ubiquitin-protein ligase TRIM7 — Q9C029 (reviewed: Q9C029)

Alternative names: Glycogenin-interacting protein, RING finger protein 90, Tripartite motif-containing protein 7

All UniProt accessions (1): Q9C029

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase that have both tumor-promoting and tumor-suppressing activities and functions in several biological processes including innate immunity, regulation of ferroptosis as well as cell proliferation and migration. Acts as an antiviral effector against multiple viruses by targeting specific viral proteins for ubiquitination and degradation including norovirus NTPase protein or SARS-CoV-2 NSP5 and NSP8 proteins. Mechanistically, recognizes the C-terminal glutamine-containing motif usually generated by viral proteases that process the polyproteins and trigger their ubiquitination and subsequent degradation. Mediates ‘Lys-63’-linked polyubiquitination and stabilization of the JUN coactivator RNF187 in response to growth factor signaling via the MEK/ERK pathway, thereby regulating JUN transactivation and cellular proliferation. Promotes the TLR4-mediated signaling activation through its E3 ligase domain leading to production of pro-inflammatory cytokines and type I interferon. Also plays a negative role in the regulation of exogenous cytosolic DNA virus-triggered immune response. Mechanistically, enhances the ‘Lys-48’-linked ubiquitination of STING1 leading to its proteasome-dependent degradation. Mediates the ubiquitination of the SIN3-HDAC chromatin remodeling complex component BRMS1. Modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells by ubiquitinating NCOA4, leading to its degradation. (Microbial infection) Promotes Zika virus replication by mediating envelope protein E ubiquitination.

Subunit / interactions. Forms homodimers. Interacts with GNIP2. Interacts with GYG1. Interacts with RNF187 (via C-terminus).

Subcellular location. Nucleus. Cytoplasm. Golgi apparatus.

Tissue specificity. Skeletal muscle and placenta, at lower levels in heart, brain and pancreas. Isoform 1 is widely expressed with high level in testis, kidney and heart.

Post-translational modifications. Phosphorylated at Ser-107 by RPS6KA5/MSK1, which stimulates the ubiquitin ligase activity. Auto-ubiquitinates via ‘Lys-63’-linked polyubiquitination.

Domain organisation. The B30.2 domain mediates interaction with GYG1. The coiled-coil region mediates homodimerization and heterodimerization.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the TRIM/RBCC family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9C029-2	1, GNIP1	yes
Q9C029-3	2, GNIP2
Q9C029-4	3, GNIP3
Q9C029-1	4, TRIM7

RefSeq proteins (6): NP_203128, NP_976038, NP_976039, NP_976040, NP_976041, NP_976042 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000315	Znf_B-box	Domain
IPR001841	Znf_RING	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003879	Butyrophylin_SPRY	Domain
IPR006574	PRY	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR020457	Znf_B-box_chordata	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050143	TRIM/RBCC	Family

Pfam: PF00622, PF00643, PF13765, PF15227

UniProt features (54 total): strand 19, mutagenesis site 11, splice variant 5, sequence variant 5, binding site 4, turn 3, zinc finger region 2, chain 1, domain 1, coiled-coil region 1, helix 1, modified residue 1

Structure

Experimental structures (PDB)

20 structures.

PDB	Method	Resolution (Å)
7W0Q	X-RAY DIFFRACTION	1.1
7X70	X-RAY DIFFRACTION	1.25
7X6Y	X-RAY DIFFRACTION	1.39
7W0S	X-RAY DIFFRACTION	1.4
7X6Z	X-RAY DIFFRACTION	1.43
9HIN	X-RAY DIFFRACTION	1.55
7W0T	X-RAY DIFFRACTION	1.57
6UMA	X-RAY DIFFRACTION	1.6
8R5B	X-RAY DIFFRACTION	1.6
8R5C	X-RAY DIFFRACTION	1.6
8A5L	X-RAY DIFFRACTION	1.62
7OVX	X-RAY DIFFRACTION	1.7
7Y3A	X-RAY DIFFRACTION	1.7
7Y3C	X-RAY DIFFRACTION	1.71
7Y3B	X-RAY DIFFRACTION	1.76
6UMB	X-RAY DIFFRACTION	1.8
8R5D	X-RAY DIFFRACTION	1.8
7OW2	X-RAY DIFFRACTION	2.17
8A8X	X-RAY DIFFRACTION	2.37
8A5M	X-RAY DIFFRACTION	2.92

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C029-F1	86.56	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 130; 133; 152; 158

Post-translational modifications (1): 107

Mutagenesis-validated functional residues (11):

Position	Phenotype
29	abolishes ubiquitination and stabilization of rnf187; when associated with a-32.
32	abolishes ubiquitination and stabilization of rnf187; when associated with a-29.
57	abolishes ubiquitination and stabilization of rnf187.
107	abolishes phosphorylation by rps6ka5/msk1. reduced ubiquitination activity towards rnf187.
383	complete loss of substrate binding.
385	complete loss of substrate binding.
423	complete loss of interaction with gyg1.
426	complete loss of substrate binding.
436	complete loss of substrate binding.
499	complete loss of interaction with gyg1.
501	complete loss of interaction with gyg1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 118 (showing top): BENPORATH_ES_WITH_H3K27ME3, MODULE_255, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MODULE_317, WATANABE_COLON_CANCER_MSI_VS_MSS_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_DEFENSE_RESPONSE_TO_VIRUS, GOBP_RESPONSE_TO_VIRUS, MODULE_69, SANSOM_APC_MYC_TARGETS

GO Biological Process (4): protein ubiquitination (GO:0016567), innate immune response (GO:0045087), antiviral innate immune response (GO:0140374), defense response to virus (GO:0051607)

GO Molecular Function (5): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
protein modification by small protein conjugation	1
immune response	1
defense response to symbiont	1
innate immune response	1
defense response to virus	1
defense response	1
response to virus	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1

Protein interactions and networks

STRING

640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIM7	GYG2	O15488	938
TRIM7	GYG1	P46976	938
TRIM7	TRAT1	Q6PIZ9	830
TRIM7	BBOX1	O75936	748
TRIM7	BRMS1	Q9HCU9	493
TRIM7	ARMC12	Q5T9G4	459
TRIM7	INIP	Q9NRY2	458
TRIM7	TRIM46	Q7Z4K8	431
TRIM7	PYURF	Q96I23	425
TRIM7	KLHL40	Q2TBA0	414
TRIM7	BECN1	Q14457	397
TRIM7	BEAN1	Q3B7T3	395
TRIM7	AKTIP	Q9H8T0	393
TRIM7	SLC26A3	P40879	392
TRIM7	TUBGCP4	Q9UGJ1	387

IntAct

95 interactions, top by confidence:

A	B	Type	Score
TRIM16	TRIM16L	psi-mi:“MI:0914”(association)	0.710
SIAH1	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	SIAH1	psi-mi:“MI:0915”(physical association)	0.560
GTF2A2	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
BCAM	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
AQP1	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	CFL2	psi-mi:“MI:0915”(physical association)	0.560
RNASE1	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	MAD2L2	psi-mi:“MI:0915”(physical association)	0.560
NAA35	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
CRYGC	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
CDK13	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
RAB2A	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRMT10A	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	RSPH14	psi-mi:“MI:0915”(physical association)	0.560
OTUD6A	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
NABP1	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	IRAK4	psi-mi:“MI:0915”(physical association)	0.560
TP53I13	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
RIN1	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7	CTNNAL1	psi-mi:“MI:0915”(physical association)	0.560
RWDD2B	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TRIM7		psi-mi:“MI:0915”(physical association)	0.550
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530
HAO2	TRIM7	psi-mi:“MI:0915”(physical association)	0.400
TRIM7	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
HSF2	TRIM7	psi-mi:“MI:0915”(physical association)	0.400
TRIM7	AARSD1	psi-mi:“MI:0915”(physical association)	0.400
Rpl35	RPS6	psi-mi:“MI:0914”(association)	0.350

BioGRID (140): TRIM7 (Two-hybrid), TRIM7 (Affinity Capture-MS), TRIM7 (Affinity Capture-MS), TRIM7 (Affinity Capture-MS), TRIM7 (Biochemical Activity), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), TRIM7 (Two-hybrid), RWDD2B (Two-hybrid)

ESM2 similar proteins: A0JN74, A6NCK2, A6NGJ6, A6NI03, B1H278, K7N6K2, O00478, O00481, P14373, P19474, Q13410, Q1ACD5, Q1ACD6, Q1ACD7, Q1ACD8, Q1XHU0, Q2YEM8, Q2YEM9, Q3ZEE5, Q587N6, Q5C8T6, Q5C8T8, Q5C8U1, Q5D7I9, Q5D7J0, Q5D7J1, Q5NCC9, Q5R996, Q62158, Q6MFZ5, Q7YR33, Q7YRV4, Q80V85, Q8BGE7, Q8NG06, Q923T7, Q96BQ3, Q96F44, Q99PP6, Q99PQ2

Diamond homologs: A0A2P1BRP3, A0A2P1BRQ0, A0JN74, A0ZSK3, A0ZSK4, B1H278, O19085, O95361, P14373, P19474, Q02084, Q1XHU0, Q309B1, Q5R760, Q5R7W8, Q62158, Q62556, Q7KYR7, Q86WT6, Q8N7C3, Q8WVV5, Q91431, Q91453, Q96F44, Q98989, Q98993, Q99PP9, Q99PQ2, Q9C029, Q9HCM9, Q9JLN5, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NK02, A6NLI5, C9J1S8, K7N6K2, O00635

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	TRIM7	ubiquitination
TRIM7	“up-regulates quantity by stabilization”	RNF187	ubiquitination
TRIM7	“down-regulates quantity by destabilization”	STING1	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1321 predictions. Top by Δscore:

Variant	Effect	Δscore
5:181195673:CTCCA:C	acceptor_gain	1.0000
5:181195674:TCCA:T	acceptor_gain	1.0000
5:181195675:CCA:C	acceptor_gain	1.0000
5:181195675:CCAC:C	acceptor_gain	1.0000
5:181195676:CA:C	acceptor_gain	1.0000
5:181195676:CAC:C	acceptor_gain	1.0000
5:181195677:AC:A	acceptor_loss	1.0000
5:181195678:C:CC	acceptor_gain	1.0000
5:181195678:CTGC:C	acceptor_loss	1.0000
5:181199091:TCACC:T	donor_loss	1.0000
5:181199092:CACC:C	donor_loss	1.0000
5:181199115:TTC:T	acceptor_gain	1.0000
5:181199116:TC:T	acceptor_gain	1.0000
5:181199116:TCC:T	acceptor_loss	1.0000
5:181199117:CC:C	acceptor_gain	1.0000
5:181199118:C:CA	acceptor_loss	1.0000
5:181199118:C:CC	acceptor_gain	1.0000
5:181199846:CTTA:C	donor_loss	1.0000
5:181199847:TTA:T	donor_loss	1.0000
5:181199848:TAC:T	donor_loss	1.0000
5:181199849:A:T	donor_loss	1.0000
5:181199850:C:CT	donor_loss	1.0000
5:181200088:C:CT	acceptor_gain	1.0000
5:181200088:C:T	acceptor_gain	1.0000
5:181200089:A:T	acceptor_gain	1.0000
5:181203561:T:A	donor_gain	1.0000
5:181203638:CTC:C	acceptor_gain	1.0000
5:181204584:CTCA:C	donor_loss	1.0000
5:181204585:TCAC:T	donor_loss	1.0000
5:181204586:CA:C	donor_loss	1.0000

AlphaMissense

3288 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:181204967:G:C	F48L	0.999
5:181204967:G:T	F48L	0.999
5:181204969:A:G	F48L	0.999
5:181195562:G:C	F380L	0.998
5:181195562:G:T	F380L	0.998
5:181195564:A:G	F380L	0.998
5:181205026:A:G	C29R	0.998
5:181204970:G:C	S47R	0.997
5:181204970:G:T	S47R	0.997
5:181204972:T:G	S47R	0.997
5:181205017:A:G	C32R	0.997
5:181205025:C:T	C29Y	0.997
5:181204666:A:G	C149R	0.996
5:181204966:A:G	C49R	0.996
5:181204968:A:G	F48S	0.996
5:181205024:G:C	C29W	0.996
5:181195505:C:A	W399C	0.995
5:181195505:C:G	W399C	0.995
5:181195507:A:G	W399R	0.995
5:181195507:A:T	W399R	0.995
5:181204665:C:T	C149Y	0.995
5:181204879:A:G	C78R	0.995
5:181204973:G:C	H46Q	0.995
5:181204973:G:T	H46Q	0.995
5:181204995:G:T	P39Q	0.995
5:181205015:G:C	C32W	0.995
5:181205016:C:T	C32Y	0.995
5:181204965:C:T	C49Y	0.994
5:181204968:A:C	F48C	0.994
5:181205004:A:G	F36S	0.994

dbSNP variants (sampled 300 via entrez): RS1000065934 (5:181205706 A>G), RS1000549430 (5:181199910 A>T), RS1000769245 (5:181196057 T>C), RS1000955777 (5:181204295 G>A,C), RS1000956790 (5:181201175 C>G,T), RS1000965731 (5:181206744 C>A,G), RS1001123089 (5:181204478 C>T), RS1001442794 (5:181198464 C>G), RS1001844996 (5:181202865 C>G,T), RS1001887403 (5:181197134 C>T), RS1002002173 (5:181203231 A>T), RS1002107238 (5:181197088 G>A), RS1002143576 (5:181203748 G>A,C,T), RS1002607239 (5:181206934 T>C), RS1002744943 (5:181204774 G>C)

Disease associations

OMIM: gene MIM:609315 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression	3
Benzo(a)pyrene	decreases expression, decreases methylation, affects methylation	2
Cadmium Chloride	decreases expression	2
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
entinostat	increases expression	1
abrine	decreases expression	1
NSC 689534	affects binding, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Carcinogens	decreases expression	1
Copper	decreases expression, affects binding	1
Hydrogen Peroxide	affects expression	1
Mutagens	decreases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Tetradecanoylphorbol Acetate	decreases reaction, increases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	decreases methylation	1
Particulate Matter	increases abundance, decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2JQ	Abcam HeLa TRIM7 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.